In the Winter 2022 edition of “European Biotechnology“ magazine, from December, the cover story “Biotech Financing – Crisis? What Crisis?” focuses on 2022 as “the most difficult year for mergers and acquisitions in biotech since 2018…”
In an interview with Dr. Georg Kääb, our CEO, Arno Fuchs, describes his view on the current development in the US and Europe.
Read the full article on here.
